Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

BACKGROUND: Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluated changes in laboratory parameters and immunopharmacodynamic markers in patien...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Exp Hematol Oncol
Main Authors: Nägele, Virginie, Kratzer, Andrea, Zugmaier, Gerhard, Holland, Chris, Hijazi, Youssef, Topp, Max S., Gökbuget, Nicola, Baeuerle, Patrick A., Kufer, Peter, Wolf, Andreas, Klinger, Matthias
Formáid: Artigo
Teanga:Inglês
Foilsithe: BioMed Central 2017
Ábhair:
Research
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5437652/
https://ncbi.nlm.nih.gov/pubmed/28533941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-017-0074-5
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla